Shashi Kumar, MD
Allergy · Huntsville, ALNPI 1083619225
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.3% of the total across 409 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 23 manufacturers, the largest accounting for just 21.0% — the pattern of someone who eats at a lot of different presentations.
Across 409 payments — averaging $20.48 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$2K
- GSK$1K
- CSL Behring$1K
- Takeda Pharmaceuticals U.S.A., Inc.$762
- Genentech USA, Inc.$579
- Novartis$510
- plus $2K from 17 others
What the payments were for
- Food & beverage$8,22998%
- Education$1462%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 96 | $1,761 |
| GSK | 82 | $1,397 |
| CSL Behring | 37 | $1,077 |
| Takeda Pharmaceuticals U.S.A., Inc. | 35 | $762 |
| Genentech USA, Inc. | 22 | $579 |
| Novartis | 25 | $510 |
| Sanofi | 18 | $443 |
| Optinose US, Inc. | 29 | $415 |
| Regeneron Healthcare Solutions, Inc. | 17 | $360 |
| Grifols USA, LLC | 12 | $264 |
| Kaleo, Inc. | 11 | $182 |
| Sanofi-aventis U.S. LLC | 2 | $146 |
| Boehringer Ingelheim | 7 | $125 |
| Alkermes, Inc. | 1 | $72 |
| Hikma Pharmaceuticals USA | 4 | $65 |
| Teva Pharmaceuticals USA, Inc. | 3 | $48 |
| Shire North American Group Inc | 2 | $43 |
| Amgen | 1 | $30 |
| Jubilant Hollisterstier LLC | 1 | $24 |
| LEO Pharma Inc. | 1 | $22 |
| Blueprint Medicines Corporation | 1 | $20 |
| Merck | 1 | $16 |
| Pfizer | 1 | $15 |
How this compares
Too few allergy providers in Alabamato place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| CuvitruImmun Glob G(Igg)/Gly/Iga Ov50 | 39 | $166,916 |
| Dupixent PenDupilumab | 16 | $58,162 |
| XolairOmalizumab | 15 | $41,689 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 21 | $15,281 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 36 | $8,937 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 14 | $5,550 |
| Azelastine Hcl | 117 | $5,470 |
| Epinephrine | 17 | $4,671 |
| Advair HfaFluticasone Propion/Salmeterol | 12 | $4,461 |
| Fluticasone Propionate | 69 | $1,653 |
| Montelukast Sodium | 83 | $1,397 |
| Mometasone Furoate | 13 | $1,295 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 27 | $602 |
| Famotidine | 12 | $217 |
| Levocetirizine Dihydrochloride | 23 | $184 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Takeda Pharmaceuticals U.S.A., Inc.Cuvitru | $762 | $166,91639 claims |
| GSKTrelegy Ellipta | $1,397 | $15,28121 claims |
| Hikma Pharmaceuticals USAEpinephrine | $65 | $4,67117 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few allergy providers in Alabamaon file to place this against a meaningful peer group, so we don't.
Other allergy in Huntsville
- John MeadowsBirmingham$204K
- Druhan HowellMobile$201K
- John ToleBirmingham$33K
- William FancherBirmingham$3K
- Lucinda PattonMobile$3K
- Valerie leMadison$1K
- Charles BrentnallSylacauga$1K
- Joseph GiannobileBirmingham$991
- Steven HelmTuscaloosa$185
- Alma HerreraMobile$19
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.